2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Fat Mass and Obesity-associated Protein (FTO)
  5. Fat Mass and Obesity-associated Protein (FTO) Inhibitor

Fat Mass and Obesity-associated Protein (FTO) Inhibitor

Fat Mass and Obesity-associated Protein (FTO) Inhibitors (17):

Cat. No. Product Name Effect Purity
  • HY-B1320
    Meclofenamic acid sodium
    		Inhibitor 99.89%
    Meclofenamic acid (Meclofenamate) sodium is a non-steroidal anti-inflammatory agent (NSAID). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat - and obesity-related enzyme (FTO). Meclofenamic acid sodium has anti-inflammatory and antitumor activities.
  • HY-129079
    TFMB-(R)-2-HG
    		Inhibitor 99.91%
    TFMB-(R)-2-HG is a cell membrane-permeable (R)-2-HG and acute myeloid leukemia (AML) oncogenic factor. TFMB-(R)-2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases such as KDM2B and FTO. TFMB-(R)-2-HG impairs cell differentiation in response to Estrogen withdrawal. TFMB-(R)-2-HG is used in acute myeloid leukemia and glioma research.
  • HY-117275
    Meclofenamic acid
    		Inhibitor 99.66%
    Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
  • HY-101082
    N6,2′-O-Dimethyladenosine
    		Inhibitor 99.93%
    N6,2′-O-Dimethyladenosine is a substrate of fat mass and obesity-associated gene (FTO) and mRNA cap modification. N6,2′-O-Dimethyladenosine dynamically regulates mRNA stability, translation efficiency, and protein expression. N6,2′-O-Dimethyladenosine can regulate obesity.
  • HY-172399
    FTO-IN-14
    		Inhibitor
    FTO-IN-14 (Compound F97) is the inhibitor for the RNA demethylase Fat mass and obesity-associated protein FTO with IC50 of 0.45 μM. FTO-IN-14 regulates the protein expression of ASB2, RARA and MYC. FTO-IN-14 exhibits antiproliferative activity in AML cancer cells (IC50 for MOLM13, NB4, HEL, OCI-AML3, MV4-11 and MONOMAC6 is 0.7-5.5 μM), induces apoptosis in NB4 cell. FTO-IN-14 exhibits antitumor activity in mouse NB4 xenograft models.
  • HY-168483
    FTO-IN-13
    		Inhibitor
    FTO-IN-13 (compound 8t) is a potent FTO inhibitor. FTO-IN-13 shows antiproliferative activity. FTO-IN-13 induces apoptosis. FTO-IN-13 decreases the protein expression of Bcl-2 and Caspase 3 active. FTO-IN-13 decreases MYC and CEBPA gene expression. FTO-IN-13 shows anticancer activity.
  • HY-149334
    ZLD115
    		Inhibitor 99.87%
    ZLD115 (compound 44) is a FB23-derivated inhibitor of Fat Mass and Obesity-associated Protein (FTO). ZLD115 is an antileukemic agent, exhibiting antiproliferative activity against leukemic cell lines.
  • HY-151106
    FTO-IN-8
    		Inhibitor 98.03%
    FTO-IN-8 (FTO-43) is a N6-methyladenosine demethylase (FTO) (fat mass- and obesity-associated protein) inhibitor with the IC50 value of 5.5 μM. FTO-IN-8 has anti-cancer cell proliferative activity.
  • HY-147011
    FTO-IN-7
    		Inhibitor 99.22%
    FTO-IN-7 (compound 17) is an inhibitor of FTO (fat mass and obesity-associated protein) with an IC50 of <1 μM. FTO-IN-7 can be used for the study of small-cell lung cancers and human bone marrow striated muscle cancer.
  • HY-117426
    MO-I-500
    		Inhibitor 99.10%
    MO-I-500 is a pharmacological of FTO inhibitor with an IC50 of 8.7 μM for the inhibition of purified FTO demethylase catalyzing demethylation of an artificial small methylated substrate. MO-I-500 can be used for the research of rare panresistant triple-negative inflammatory breast cancer.
  • HY-156405
    FTO-IN-10
    		Inhibitor
    FTO-IN-10 (compound 7) is a potent human demethylase FTO (the fat mass and obesity-associated protein) inhibitor with an IC50 of 4.5 μM. FTO-IN-10 enters the FTO’s structural domain II binding pocket through hydrophobic and hydrogen bonding interactions. FTO-IN-10 induces DNA damage and autophagic cell death in A549 cells.
  • HY-W026109
    FTO-IN-12
    		Inhibitor
    FTO-IN-12 (Compound 2) is an inhibitor of fat mass and obesity-related protein (FTO). Kd and IC50 values are 185 nM and 1.46 μM, respectively. FTO-IN-12 can be used in the study of neurodegenerative diseases.
  • HY-117275A
    Meclofenamic acid sodium hydrate
    		Inhibitor
    Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
  • HY-170668
    DDO-02267
    		Inhibitor
    DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. DDO-02267 increases N6-methyladenosine (m6A) levels and targets the ALKBH5-AXL signaling axis. DDO-02267 can serve as a probe for investigating the biological function of mRNA demethylase.
  • HY-117275R
    Meclofenamic acid (Standard)
    		Inhibitor
    Meclofenamic acid (Standard) is the analytical standard of Meclofenamic acid. This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
  • HY-B1320R
    Meclofenamic acid (sodium) (Standard)
    		Inhibitor
    Meclofenamic acid (sodium) (Standard) is the analytical standard of Meclofenamic acid (sodium). This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) sodium is a non-steroidal anti-inflammatory agent (NSAID). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat - and obesity-related enzyme (FTO). Meclofenamic acid sodium has anti-inflammatory and antitumor activities.
  • HY-131871
    Ethyl LipotF
    		Inhibitor 99.25%
    Ethyl LipotF is a selective FTO inhibitor that significant increases modified N6-methyladenosine (m6A) levels in HeLa cells in a concentration-dependent manner.